PTAB Denies Institution of IPR Proceedings Against Bayer’s Patent Covering STIVARGA®
On February 8, 2017, the PTAB denied Fustibal LLC’s ("Fustibal") petition to institute inter partes review of U.S. Patent 8,637,553 B2 ("the ’553 patent") owned by Bayer HealthCare LLC ("Bayer") (IPR2016-01490). The 553 patent has also been asserted in two district court proceedings against Teva Pharmaceuticals USA, Inc. and Apotex, Inc. In addition, the development of the compound covered by the claims of the 553 patent is the subject of an ongoing litigation with Onyx Pharmaceuticals, Inc.
Read the full article at ptablitigationblog.com